Immunome (NASDAQ:IMNM) Insider Kinney Horn Sells 1,092 Shares

Immunome, Inc. (NASDAQ:IMNM) insider Kinney Horn sold 1,092 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $25.00, for a total value of $27,300.00. Following the completion of the transaction, the insider directly owned 1,092 shares of the company’s stock, valued at $27,300. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Up 0.6%

Shares of Immunome stock opened at $24.16 on Friday. The firm has a market capitalization of $2.74 billion, a P/E ratio of -10.15 and a beta of 2.07. Immunome, Inc. has a 52 week low of $7.96 and a 52 week high of $27.65. The firm’s 50 day moving average is $21.01 and its two-hundred day moving average is $21.87.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.12. As a group, research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on IMNM. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. HC Wainwright reissued a “buy” rating on shares of Immunome in a report on Thursday. Barclays started coverage on Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price for the company. Finally, Leerink Partners dropped their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.17.

Institutional Trading of Immunome

A number of large investors have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. increased its stake in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after buying an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA grew its holdings in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after buying an additional 1,667,432 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Immunome in the 4th quarter valued at about $30,710,000. Finally, Sofinnova Investments Inc. increased its position in Immunome by 271.2% in the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after acquiring an additional 1,182,426 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.